Cite
HARVARD Citation
Fernandez, E. et al. (n.d.). P-190 Personalized Immunotherapy with Cell-Encapsulation Technology for 2nd line R/M HNSCC: Safety and Early Efficacy Data from all HNSCC patients treated with MVX-ONCO-1 in two clinical trials. Oral oncology. pp. 6-. [Online].